Results 131 to 140 of about 4,754 (217)

Lupus eritematoso tumidus y leishmaniasis: A propósito de un caso [PDF]

, 2016
Pocas veces se tiene en cuenta que la Leishmaniasis (enfermedad producida por un protozoo) y otras enfermedades de clínica similar como el Lupus Eritematoso (enfermedad de origen autoinmune) pueden presentarse en forma concomitante.
Barrio. Alejandra Beatriz, Garcia Bustos, Maria Fernanda, González Prieto, G, Monroig, Sibila, Ramos, Federico, Segura, Graciela   +5 more
core  

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia). [PDF]

Clin Infect Dis, 2021
Gómez MA, Navas A, Prieto MD, Giraldo-Parra L, Cossio A, Alexander N, Gore Saravia N.   +6 more
europepmc   +1 more source

Paediatric visceral leishmaniasis: experience of a paediatric referral center 1990-2009 [PDF]

, 2011
INTRODUCTION: Visceral Leishmaniasis (VL) is a systemic infection, endemic in many parts of the world, including Portugal. The aim is to review all cases of VL admitted to our hospital.
Dias, A, Dionísio, MT, Estevão, MH, Félix, M, Rodrigues, F   +4 more
core  

AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages. [PDF]

BMC Microbiol, 2021
Gélvez APC, Diniz Junior JAP, Brígida RTSS, Rodrigues APD.   +3 more
europepmc   +1 more source

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate. [PDF]

Front Cell Infect Microbiol, 2021
Fernández OL, Ramírez LG, Díaz-Varela M, Tacchini-Cottier F, Saravia NG.   +4 more
europepmc   +1 more source

Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions of Leishmania (Viannia) braziliensis-infected hamsters. [PDF]

Front Cell Infect Microbiol, 2023
Meira RMV, Gomes SLDS, Schaeffer E, Da Silva T, Brito ACS, Siqueira LM, Inácio JD, Almeida-Amaral EE, Da-Cruz AM, Bezerra-Paiva M, Neves RH, Rodrigues LS, Dutra PML, Costa PRR, da Silva AJM, Da-Silva SAG.   +15 more
europepmc   +1 more source

Current issues in the treatment of visceral leishmaniasis. [PDF]

, 2001
Bryceson, A
core   +1 more source

In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 1992
1. The activity of a pentavalent antimonial drug glucantime on the growth of promastigote forms of Leishmania strains involved in South American cutaneous and mucocutaneous leishmaniasis was investigated. A marked difference in susceptibility to glucantime among four different strains and cloned lines obtained from a single strain was observed. For the
E S, Moreira, M L, Petrillo-Peixoto
openaire   +1 more source

Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area. [PDF]

Front Cell Infect Microbiol, 2022
Barroso DH, Gonçalves RT, Barbosa JS, da Motta JOC, Freire GSM, Gomes CM, Sampaio RNR.   +6 more
europepmc   +1 more source

Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask

مجله دانشکده پزشکی اصفهان, 2013
Background: Pentavalent antimony compounds are the main treatment for cutaneous leishmaniasis. Usually, this drug is injected into the lesion for acute treatment, which is very painful and results in low patient compliance.
Sayed Abolfazl Mostafavi, Mohammad Ali Shatalebi, Ahmad Movahedian Attar, Hossein Hejazi, Amin Mottaghinejad, Reza Fadaei, Javad Ramezanpour, Parastuo Zarrinzamir   +7 more
doaj